The Food and Drug Administration has launched a safety study of the abortion pill mifepristone, a senior FDA official confirmed to CBS News, a step that could pave the way for the Trump administration to restrict access to the medication.

The reported study could allow the Trump administration to limit the distribution of the abortion pill by mail or telehealth services.

The full results are unlikely to be completed before November's midterm elections, the report said.

The FDA's ongoing review of mifepristone could skip over established science, health experts warn